Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
2.580
-0.410 (-13.71%)
Nov 20, 2024, 4:00 PM EST - Market closed
Adlai Nortye Employees
Adlai Nortye had 127 employees as of December 31, 2023. The number of employees decreased by 2 or -1.55% compared to the previous year.
Employees
127
Change (1Y)
-2
Growth (1Y)
-1.55%
Revenue / Employee
$39,370
Profits / Employee
-$425,709
Market Cap
95.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TELA Bio | 227 |
| Century Therapeutics | 165 |
| TriSalus Life Sciences | 112 |
| Leap Therapeutics | 54 |
| Milestone Pharmaceuticals | 47 |
| Fennec Pharmaceuticals | 29 |
| Eupraxia Pharmaceuticals | 29 |
| INmune Bio | 17 |
ANL News
- 6 months ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 6 months ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 8 months ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire
- 1 year ago - Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award - GlobeNewsWire
- 1 year ago - Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles - Seeking Alpha
- 1 year ago - Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewsWire
- 1 year ago - U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline - Seeking Alpha